8-K: Acelyrin to Merge with Alumis in All-Stock Transaction, Creating Immunology Powerhouse

Acelyrin and Alumis have agreed to merge in an all-stock transaction, aiming to create a leading late-stage clinical biopharmaceutical company focused on immune-mediated diseases.

Summary

• Acelyrin and Alumis have entered into a merger agreement where Alumis will acquire Acelyrin in an all-stock transaction.
• Acelyrin stockholders will receive 0.4274 shares of Alumis common stock for each share of Acelyrin common stock they own.
• Post-merger, Alumis stockholders are expected to own approximately 55% and Acelyrin stockholders approximately 45% of the combined company on a fully diluted basis.
• The combined company is expected to have approximately $737 million in pro forma cash as of the end of Q4 2024, extending the cash runway into 2027.
• The merger is anticipated to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.
• The combined company will operate under the Alumis name and be led by the current Alumis executive team.
• The Alumis Board will expand to nine directors, including two additional directors from Acelyrin's Board.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook on the merger, highlighting the potential for value creation and a strengthened position in the immunology market. However, it also acknowledges the inherent risks and uncertainties associated with such transactions, leading to a moderately positive sentiment score.

Positives

• The merger creates a leading late-stage clinical biopharma company focused on immune-mediated diseases.
• The combined company will have a differentiated and late-stage portfolio targeting large, well-established multi-billion dollar markets.
• The merger provides multiple, meaningful near-term catalysts.
• The combined company will be led by a deep and experienced team.
• The pro forma cash position of over $700 million as of December 31, 2024, extends the cash runway into 2027.
• The merger has the potential for substantial value accretion for the combined company.

Negatives

• The merger is subject to stockholder approvals and customary closing conditions, which could delay or prevent the transaction.
• The announcement, pendency, or completion of the merger could affect the ability to attract, motivate, retain, and hire key personnel.
• The merger may divert management's attention from ongoing business operations.
• There is a risk that the anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• The value of Alumis securities to be issued in the merger is subject to risks.
• Integrating the two companies post-closing may not occur as anticipated, and the combined company may not achieve the expected growth prospects.

Risks

• The proposed merger may not be completed in a timely manner or at all, which could adversely affect both companies.
• Required approvals of the proposed merger, including stockholder approvals, may not be received on a timely basis or at all.
• The announcement, pendency, or completion of the proposed merger could negatively impact the ability to attract and retain key personnel and maintain relationships with partners and suppliers.
• The proposed merger may divert management's attention from ongoing business operations.
• Legal proceedings related to the proposed merger could result in expense or delay.
• Economic, business, and/or competitive factors could adversely affect Alumis or Acelyrin.
• Restrictions during the pendency of the proposed merger may impact the ability to pursue certain business opportunities or strategic transactions.
• The anticipated benefits and synergies of the proposed merger may not be fully realized or may take longer to realize than expected.
• Legislative, regulatory, economic, competitive, and technological changes could impact the combined company.
• The value of Alumis securities to be issued in the proposed merger is subject to risks.
• Integration of the proposed merger post-closing may not occur as anticipated, and the combined company may not be able to achieve the expected growth prospects.
• The implementation of each company's business model and strategic plans for product candidates and pipeline faces inherent challenges.
• The scope, progress, results, and costs of developing product candidates and conducting clinical trials are subject to uncertainties.
• Obtaining and maintaining regulatory approval for product candidates involves timing and cost risks.
• The market for, adoption, pricing, and reimbursement of product candidates, if approved, are subject to uncertainties.
• Uncertainties exist in contractual relationships, including collaborations, partnerships, licensing, and the performance of third-party suppliers and manufacturers.
• The ability to establish and maintain intellectual property protection for products or avoid or defend claims of infringement is subject to risks.
• Potential delays in initiating, enrolling, or completing preclinical studies and clinical trials could occur.

Future Outlook

The combined company expects to advance its pipeline with the pro forma cash and aims for substantial value accretion. The pro forma financial plans are expected to extend the cash runway into 2027.

Management Comments

• The transaction with Alumis offers an opportunity for substantial value accretion well above the standalone value of ACELYRIN.
• The transaction maximizes the potential opportunity for lonigutamab while adding assets, resources and talent for substantial long term value accretion.
• The ACELYRIN Board Believes that the Transaction Provides Potential for Substantial Value Accretion.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation to create larger entities with more diversified pipelines and greater financial resources to navigate the costly and lengthy drug development process. This move positions the combined company to better compete in the immune-mediated diseases market.

Comparison to Industry Standards

• The merger of Acelyrin and Alumis is similar to other recent consolidations in the biotech industry, such as the acquisition of Immunomedics by Gilead Sciences, which aimed to bolster Gilead's oncology pipeline.
• The combined company's focus on immune-mediated diseases aligns with the industry's increasing interest in developing therapies for autoimmune and inflammatory conditions, a market dominated by companies like AbbVie (Humira) and Johnson & Johnson (Stelara).
• The pro forma cash position of $737 million is comparable to that of other late-stage clinical biopharma companies, providing a runway to advance clinical programs and potentially launch new products.

Stakeholder Impact

• Shareholders of Acelyrin and Alumis will be impacted by the merger through the exchange of shares and the potential for future value creation.
• Employees of both companies may experience changes in roles and responsibilities as the organizations integrate.
• Partners, suppliers, and other stakeholders may be affected by the combined company's strategic direction and operational changes.

Next Steps

• Alumis intends to file a registration statement with the SEC, including a joint proxy statement/prospectus.
• Stockholders of both Alumis and Acelyrin will need to approve the merger.
• The parties will work to satisfy other customary closing conditions to complete the transaction in the second quarter of 2025.

Key Dates